Thông tin thuốc gốc
Chỉ định và Liều dùng
Type 2 diabetes mellitus
Adult: As monotherapy or in combination with other antidiabetic agents: 50 mg bid. Max: 100 mg daily. Refer to specific product guidelines for further information on use with other antidiabetic agents.
Suy thận
Moderate to severe and ESRD patients requiring haemodialysis: 50 mg once daily.
Suy gan
Not recommended.
Cách dùng
May be taken with or without food.
Thận trọng
Patient with a history of pancreatitis. Not recommended for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis; New York Heart Association (NYHA) functional class IV. Moderate to severe renal impairment, including ESRD patients requiring haemodialysis. Not recommended for use in patients with hepatic impairment, including those with pre-treatment ALT or AST >3 times the ULN. Not considered as a substitute for insulin in patients that require them.
Tác dụng không mong muốn
Significant: Severe and disabling arthralgia, bullous and exfoliative skin lesions (including bullous pemphigoid), acute pancreatitis; hypoglycaemia (particularly during combination therapy with sulfonylureas). Rarely, hepatic dysfunction (e.g. hepatitis, jaundice, increase in AST or ALT 3 times the upper limit of normal [ULN]).
Gastrointestinal disorders: Nausea, constipation.
General disorders and administration site conditions: Fatigue, peripheral oedema.
Musculoskeletal and connective tissue disorders: Myalgia.
Nervous system disorders: Dizziness, headache.
Respiratory, thoracic and mediastinal disorders: Rarely, upper respiratory tract infection, nasopharyngitis.
Skin and subcutaneous tissue disorders: Urticaria.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor LFTs (before initiation, every 3 months for the 1st year of treatment, and as necessary thereafter), renal function (before initiation and as necessary thereafter), HbA1c (twice a year for those who have stable glycaemic control and are meeting the treatment goals, quarterly for those not meeting the treatment goals or with changes in therapy), plasma glucose. Assess for signs and symptoms of pancreatitis (e.g. persistent severe abdominal pain, nausea, vomiting, anorexia), and heart failure.
Quá liều
Symptoms: Muscle pain, mild and transient paraesthesia, fever, oedema (e.g. feet oedema), transient increase in lipase levels; increased creatine phosphokinase (CPK), AST, C-reactive protein (CRP), and myoglobin levels. Management: Supportive treatment.
Tương tác
Increased risk of hypoglycaemia during combination therapy with sulfonylureas; consider lowering the dose of sulfonylureas. May increase the risk of angioedema with ACE-inhibitors. Thiazides, corticosteroids, thyroid products, and sympathomimetics may decrease the hypoglycaemic effect of vildagliptin.
Tác dụng
Mechanism of Action: Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), it causes an increase in fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
Duration: DPP-4 inhibition (>50%): Approx 14 hours.
Absorption: Rapidly absorbed. Bioavailability: 85%. Time to peak plasma concentration: Approx 1.75 hours (fasted); 2.5 hours (fed).
Distribution: Equally distributed between plasma and RBC. Plasma protein binding: 9.3%.
Metabolism: Undergoes hydrolysis in the kidney to LAY151 (major inactive metabolite of the cyano moiety) and other metabolites.
Excretion: Via urine (approx 85%; 23% as unchanged drug); faeces (15%). Elimination half-life: Approx 3 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 6918537, Vildagliptin. Accessed Oct. 25, 2023.

Bảo quản
Store below 30°C. Protect from moisture.
Phân loại MIMS
Thuốc trị đái tháo đường
Phân loại ATC
A10BH02 - vildagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Vildagliptin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/03/2022.

Buckingham R (ed). Vildagliptin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/03/2022.

Galvus (Novartis Corporation [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 04/03/2022.

Galvus 50 mg Tablets (Novartis Pharmaceuticals UK Limited). MHRA. Accessed 04/03/2022.

Joint Formulary Committee. Vildagliptin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/03/2022.

Novartis New Zealand Limited. Galvus 50 mg Tablets data sheet 01 July 2020. Medsafe. Accessed 04/03/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vildagliptin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Galvus
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in